Related Experiment Video

Updated: Aug 9, 2026

The 6-hydroxydopamine Rat Model of Parkinson's Disease
08:10

The 6-hydroxydopamine Rat Model of Parkinson's Disease

Published on: October 27, 2021

Effect of chronic amphetamine exposure on stereotyped behavior: implications for pathogenesis of l-dopa-induced

H L Klawans, P Crossett, N Dana

    Advances in Neurology
    |January 1, 1975
    PubMed

    More Related Videos

    Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease06:45

    Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

    Published on: October 4, 2021

    Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease05:51

    Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

    Published on: October 14, 2021

    Related Concept Videos

    Adrenergic Agonists: Indirect-Acting Agents01:25

    Adrenergic Agonists: Indirect-Acting Agents

    Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
    One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
    Drugs Affecting Neurotransmitter Synthesis01:29

    Drugs Affecting Neurotransmitter Synthesis

    Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
    Parkinson's Disease: Overview01:15

    Parkinson's Disease: Overview

    Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
    Parkinson's Disease: Treatment01:24

    Parkinson's Disease: Treatment

    Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
    Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
    Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

    Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

    Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
    Attention-Deficit/Hyperactivity Disorder01:30

    Attention-Deficit/Hyperactivity Disorder

    Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
    Diagnostic Criteria and Symptoms
    To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.